Justin M. David, Ph.D.
Affiliations: | 2013 | Department of Biological Sciences | University of Delaware, Newark, DE, United States |
Area:
Cell Biology, Molecular BiologyGoogle:
"Justin David"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Kenneth L. van Golen | grad student | 2013 | University of Delaware | |
| (Development of gramicidin A as a novel therapeutic agent for renal cell carcinoma.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Garman B, Jiang C, Daouti S, et al. (2023) Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands. Frontiers in Immunology. 14: 1151748 |
| Zeligs KP, Morelli MP, David JM, et al. (2020) Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer. Frontiers in Oncology. 10: 805 |
| Fantini M, David JM, Annunziata CM, et al. (2020) The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biotherapy & Radiopharmaceuticals |
| Fantini M, David JM, Wong HC, et al. (2019) An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells. Cancer Biotherapy & Radiopharmaceuticals |
| Arlen PM, Fantini M, David J, et al. (2019) Abstract 3947: Mechanisms of action of a neoantigen-targeting antibody NEO-201 Cancer Research. 79: 3947-3947 |
| Fantini M, David JM, Wong HC, et al. (2018) Abstract 619: ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NEO-201 against human carcinoma cells Cancer Research. 78: 619-619 |
| David JM, Fantini M, Annunziata CM, et al. (2018) Abstract 3821: The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the inhibitory CEACAM5/CEACAM1 immune checkpoint pathway Cancer Research. 78: 3821-3821 |
| Fantini M, David JM, Saric O, et al. (2017) Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas. Frontiers in Immunology. 8: 1899 |
| David JM, Dominguez C, McCampbell KK, et al. (2017) A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology. 6: e1349589 |
| Dominguez C, McCampbell KK, David JM, et al. (2017) Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. Jci Insight. 2 |